Source: GlobeNewswire

Press Release: LogicBio : LogicBio Reports Second Quarter 2019 Financial Results and Provides Business Updates

CAMBRIDGE, Mass., Aug. 13, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today reported financial results and provided a corporate update for the second quarter ended June 30, 2019.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Frederic Chereau's photo - President & CEO of LogicBio

President & CEO

Frederic Chereau

CEO Approval Rating

82/100

LogicBio is a biotechnology company that develops genetic medicines to treat rare pediatric diseases. Read more